Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation HAYES, Inc. Guardant360 (Guardant Health Inc.) Lansdale: HAYES, Inc. Genetic Testing Publication. 2016 Authors' objectives Guardant360 is a liquid biopsy noninvasive blood screen used to identify actionable alterations across all solid tumor sites and provide a report, which identifies Food and Drug Administration (FDA)-approved treatments and clinical trials to help guide treatment decisions. The focus of this review is to assess the evidence that supports the use of Guardant360 as a decision-making tool, which identifies potentially actionable genetic mutations to help guide treatment options. Indexing Status Subject indexing assigned by CRD MeSH Biopsy; Decision Making; Humans; Mutation; Neoplasms; United States Food and Drug Administration Language Published English Country of organisation United States English summary An English language summary is available. Address for correspondence HAYES, Inc., 157 S. Broad Street, Suite 200, Lansdale, PA 19446, USA. Tel: 215 855 0615; Fax: 215 855 5218 Email: hayesinfo@hayesinc.com AccessionNumber 32017000084 Date abstract record published 06/01/2017 |